stockrowWindtree Therapeutics, Inc.
WINT Healthcare Biotechnology
- EPS
- +99.5%
- Free cash flow
- +1.12%
Quarter to September 2025, against a year earlier
Follow WINT
Alert me
Windtree Therapeutics, Inc. (WINT) Altman Z-score
Windtree Therapeutics, Inc.'s Altman Z-score for fiscal 2019 is −6.69, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2019 | −6.69 | (35,480.67) |
| FY2018 | 35473.98 | 22,939.73 |
| FY2017 | 12534.26 | (9,226.98) |
| FY2016 | 21761.23 | (914,183.61) |
| FY2015 | 935944.84 | — |
How fiscal 2019’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.13 | — | 0.16 | |
| Retained earnings / total assets | (5.76) | — | −8.06 | |
| EBIT / total assets | (0.21) | — | −0.69 | |
| Market value of equity / total liabilities | 3.16 | — | 1.90 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −6.69 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −17.51 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| APVO Aptevo Therapeutics Inc. compare | 256,174× |
| EOCN Eocene Ltd. compare | 26.9× |
| WINT Windtree Therapeutics, Inc. | −6.7× |
| HCWB HCW Biologics Inc. compare | −8.8× |
| BIORQ Biora Therapeutics, Inc. compare | −51.3× |
| VIVS VivoSim Labs, Inc. compare | −71.7× |
| CLDI Calidi Biotherapeutics, Inc. compare | −85.8× |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
| SLXN Silexion Therapeutics Corp compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets